© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Roche Holding AG (RHHBY) stock declined over -0.36%, trading at $53.19 on OTC, down from the previous close of $53.38. The stock opened at $52.95, fluctuating between $52.90 and $53.46 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | 52.99 | 53.53 | 52.90 | 53.19 | 1.49M |
| Sep 09, 2026 | 54.07 | 54.29 | 53.37 | 53.38 | 1.18M |
| Sep 08, 2026 | 54.24 | 54.42 | 53.87 | 54.07 | 1.3M |
| Sep 04, 2026 | 54.58 | 55.18 | 54.52 | 54.96 | 855.86K |
| Sep 03, 2026 | 55.63 | 55.63 | 54.72 | 55.25 | 2.16M |
| Sep 02, 2026 | 53.83 | 54.24 | 53.60 | 53.82 | 3.12M |
| Sep 01, 2026 | 53.81 | 54.04 | 53.07 | 53.09 | 5.09M |
| Aug 31, 2026 | 54.81 | 54.81 | 53.36 | 53.64 | 6.5M |
| Aug 28, 2026 | 55.88 | 55.89 | 55.08 | 55.19 | 1.07M |
| Aug 27, 2026 | 56.71 | 56.71 | 56.22 | 56.37 | 731.94K |
| Aug 26, 2026 | 57.30 | 57.52 | 56.86 | 56.87 | 902.04K |
| Aug 25, 2026 | 57.80 | 58.47 | 57.64 | 58.47 | 1.01M |
| Aug 24, 2026 | 57.48 | 57.72 | 57.42 | 57.51 | 1.72M |
| Aug 21, 2026 | 57.33 | 58.58 | 57.33 | 58.21 | 3.29M |
| Aug 20, 2026 | 57.92 | 58.25 | 57.02 | 57.26 | 5.37M |
| Aug 19, 2026 | 56.50 | 58.41 | 56.49 | 58.24 | 2.09M |
| Aug 18, 2026 | 55.49 | 55.69 | 55.27 | 55.52 | 3.98M |
| Aug 17, 2026 | 54.88 | 55.39 | 54.56 | 54.62 | 1.84M |
| Aug 14, 2026 | 54.60 | 54.88 | 54.43 | 54.52 | 1.48M |
| Aug 13, 2026 | 56.19 | 56.21 | 55.38 | 55.44 | 2.45M |
Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium. Its pharmaceutical division is dedicated to creating and supplying a diverse array of therapeutic remedies. These target a broad spectrum of medical fields, including oncology, neuroscience, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments. The comprehensive product line further extends to treatments for specific conditions like infectious diseases, anemia, various dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation-related needs. Within its diagnostics segment, Roche develops and markets a wide variety of laboratory-based tests designed to identify and monitor numerous illnesses. These include, but are not limited to, cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. Additionally, the company is a provider of essential diagnostic instruments and reagents. Established in 1896, Roche Holding AG maintains its corporate headquarters in Basel, Switzerland.
| Employees | 103249 |
| Beta | 0.35 |
| Sales or Revenue | $60.44B |
| 5Y Sales Change% | 0.086% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |